Teva hit with $503 million EU antitrust fine for disparaging rival product
By Sudip Kar-Gupta BRUSSELS (Reuters) -Teva, the world’s largest generic drugmaker, was hit on Thursday with a 462.6 million euro ($503 million) EU antitrust fine for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone. Teva said it planned to appeal against the judgment. The European Commission said it had …
Teva hit with $503 million EU antitrust fine for disparaging rival product Read More »









